"We entered into a partnership with MEVAC over a decade ago and are thrilled to become the majority shareholder," said Chris Nelson, president and CEO of Kemin Industries. "Kemin and MEVAC share the goal of transforming lives and creating a sustainable future - one in which non-antibiotic alternatives are becoming more and more important to customers. By extending our partnership to MEVAC's sister company, UVAC, we can do even more to bring our innovations to animal vaccines."
Having first invested in MEVAC in 2010, Kemin has increased its participation in the Egyptian-based company over the years. In 2019, Kemin expanded its share in MEVAC and received the right to distribute its vaccines globally, outside Arabic-speaking countries in the Middle East already served by MEVAC.
"As Kemin has grown its partnership with MEVAC, our capabilities and technologies have expanded as well and we are thrilled to bring this beneficial cooperation to UVAC," said Dr. Magdy El Sayed, founder of MEVAC and UVAC. "We share a commitment to advancing technology and accessibility of animal vaccines and together, we can create an even greater impact."
As part of its investment in MEVAC, Kemin has access to a modern vaccine plant with production and R&D capabilities to support future growth. UVAC, MEVAC's sister company — also based in Egypt — was established to produce foot-and-mouth disease and tissue-culture vaccines for animals as well as human vaccines.
"Over the past decade, MEVAC has proven to be an excellent partner for Kemin as we enter the animal vaccine market. Animal production is continuing to evolve and by working together, Kemin and MEVAC have been able to introduce innovation to animal vaccines," said GS Ramesh, global group president of Kemin Animal Nutrition and Health. "As our work with MEVAC has yielded such beneficial results, we are looking forward to bringing this same dedication and drive to our collaboration with UVAC."
Visit Kemin at: www.kemin.com